600535.SS
Tasly Pharmaceutical Group Co., Ltd [600535.SS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
600535.SS Stock Summary
Top 10 Correlated ETFs
600535.SS
Top 10 Correlated Stocks
600535.SS
In the News
600535.SS Financial details
Company Rating
Buy
Market Cap
22.95B
Income
1.11B
Revenue
9.06B
Book val./share
8.3
Cash/share
2.93
Dividend
0.33
Dividend %
1.99%
Employees
9.18K
Optionable
No
Shortable
Yes
Earnings
16 Apr 2024
P/E
22.25
Forward P/E
-
PEG
-4.27
P/S
2.74
P/B
1.99
P/C
5.26
P/FCF
32.13
Quick Ratio
2.58
Current Ratio
3.16
Debt / Equity
0.28
LT Debt / Equity
0.14
-
-
EPS (TTM)
0.75
EPS next Y
-
EPS next Q
-
EPS this Y
-114.65%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-13.74%
Revenue Q/Q
-5.72%
EPS Q/Q
-26.67%
-
-
-
-
SMA20
-5.88%
SMA50
6.67%
SMA100
6.67%
Inst Own
-
Inst Trans
-
ROA
6%
ROE
9%
ROC
0.09%
Gross Margin
66%
Oper. Margin
15%
Profit Margin
12%
Payout
50%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
12.88-18.0
52W High
-14.33%
52W Low
+28.5%
RSI
40
Rel Volume
1.1
Avg Volume
14.74M
Volume
16.28M
Perf Week
-3.02%
Perf Month
-10.71%
Perf Quarter
14.99%
Perf Half Y
7.16%
-
-
-
-
Beta
0.39
-
-
Volatility
0.26%, 0.66%
Prev Close
1.31%
Price
15.42
Change
2.73%
600535.SS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 11.93 | 12.6 | 9.03 | 5.3 | 5.75 | |
| Net income per share | 1.02 | 0.66 | 0.75 | 1.57 | -0.23 | |
| Operating cash flow per share | 0.99 | 1.11 | 1.19 | 1.87 | 1.53 | |
| Free cash flow per share | 0.47 | 0.63 | 0.92 | 1.48 | 1.26 | |
| Cash per share | 1.96 | 1.29 | 1.41 | 2.52 | 2.83 | |
| Book value per share | 6.99 | 7.38 | 7.97 | 8.65 | 8.3 | |
| Tangible book value per share | 6.28 | 6.57 | 7.13 | 7.67 | 7.4 | |
| Share holders equity per share | 6.99 | 7.38 | 7.97 | 8.65 | 8.3 | |
| Interest debt per share | 6.66 | 5.66 | 2.05 | 1.18 | 1.49 | |
| Market cap | 26.96B | 23.25B | 22.23B | 23.8B | 16.09B | |
| Enterprise value | 33.37B | 29.45B | 23.05B | 23.19B | 15.14B | |
| P/E ratio | 17.45 | 23.22 | 19.74 | 10.09 | -47.21 | |
| Price to sales ratio | 1.5 | 1.22 | 1.64 | 2.99 | 1.87 | |
| POCF ratio | 18.05 | 13.84 | 12.41 | 8.5 | 7.04 | |
| PFCF ratio | 37.78 | 24.49 | 16.08 | 10.68 | 8.55 | |
| P/B Ratio | 2.56 | 2.09 | 1.86 | 1.83 | 1.3 | |
| PTB ratio | 2.56 | 2.09 | 1.86 | 1.83 | 1.3 | |
| EV to sales | 1.86 | 1.55 | 1.7 | 2.92 | 1.76 | |
| Enterprise value over EBITDA | 11.37 | 13.24 | 9.54 | 6.47 | 8.46 | |
| EV to operating cash flow | 22.34 | 17.53 | 12.87 | 8.28 | 6.63 | |
| EV to free cash flow | 46.76 | 31.02 | 16.67 | 10.4 | 8.05 | |
| Earnings yield | 0.06 | 0.04 | 0.05 | 0.1 | -0.02 | |
| Free cash flow yield | 0.03 | 0.04 | 0.06 | 0.09 | 0.12 | |
| Debt to equity | 0.91 | 0.73 | 0.23 | 0.13 | 0.17 | |
| Debt to assets | 0.38 | 0.34 | 0.17 | 0.1 | 0.13 | |
| Net debt to EBITDA | 2.18 | 2.79 | 0.34 | -0.17 | -0.53 | |
| Current ratio | 2.09 | 1.91 | 3.26 | 4.99 | 4.38 | |
| Interest coverage | 3.99 | 4.08 | 5.14 | 35.31 | 19.78 | |
| Income quality | 0.94 | 1.67 | 1.64 | 1.16 | -6.71 | |
| Dividend Yield | 0.03 | 0.04 | 0.04 | 0.03 | 0.03 | |
| Payout ratio | 0.56 | 0.9 | 0.71 | 0.26 | -1.63 | |
| Sales general and administrative to revenue | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | |
| Research and developement to revenue | 0.03 | 0.03 | 0.05 | 0.07 | 0.1 | |
| Intangibles to total assets | 0.07 | 0.08 | 0.1 | 0.11 | 0.1 | |
| Capex to operating cash flow | -0.52 | -0.43 | -0.23 | -0.2 | -0.18 | |
| Capex to revenue | -0.04 | -0.04 | -0.03 | -0.07 | -0.05 | |
| Capex to depreciation | -2.19 | -1.89 | -0.76 | -1.17 | -0.78 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0.01 | |
| Graham number | 12.69 | 10.5 | 11.59 | 17.48 | 6.52 | |
| ROIC | 0.08 | 0.07 | 0.07 | 0.16 | 0.18 | |
| Return on tangible assets | 0.07 | 0.05 | 0.08 | 0.16 | -0.02 | |
| Graham Net | -0.52 | 0 | 1.98 | 2.82 | 2.54 | |
| Working capital | 9.3B | 7.88B | 6.41B | 7.39B | 7.12B | |
| Tangible asset value | 9.47B | 9.91B | 10.72B | 11.52B | 11.07B | |
| Net current asset value | 3.86B | 4.39B | 5.13B | 6.02B | 5.47B | |
| Invested capital | 0.91 | 0.73 | 0.23 | 0.13 | 0.17 | |
| Average receivables | 11.36B | 11.98B | 8.81B | 4.79B | 3.65B | |
| Average payables | 2.9B | 2.91B | 1.76B | 706.45M | 798.73M | |
| Average inventory | 2.31B | 2.47B | 1.95B | 1.45B | 1.53B | |
| Days sales outstanding | 244.42 | 228.72 | 153.69 | 177.51 | 145.64 | |
| Days payables outstanding | 94.46 | 79.51 | 31.01 | 99.32 | 102.65 | |
| Days of inventory on hand | 76.22 | 71.22 | 61.34 | 211.01 | 179.08 | |
| Receivables turnover | 1.49 | 1.6 | 2.37 | 2.06 | 2.51 | |
| Payables turnover | 3.86 | 4.59 | 11.77 | 3.68 | 3.56 | |
| Inventory turnover | 4.79 | 5.13 | 5.95 | 1.73 | 2.04 | |
| ROE | 0.15 | 0.09 | 0.09 | 0.18 | -0.03 | |
| Capex per share | -0.52 | -0.48 | -0.27 | -0.38 | -0.27 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.4 | 1.67 | 1.39 | 1.55 | 1.46 | |
| Net income per share | 0.04 | 0.05 | 0.18 | 0.3 | 0.22 | |
| Operating cash flow per share | 0.04 | 0.05 | 0.18 | 0.47 | 0.17 | |
| Free cash flow per share | -0.05 | -0.03 | 0.03 | 0.43 | 0.1 | |
| Cash per share | 2.28 | 2.84 | 2.98 | 2.72 | 2.93 | |
| Book value per share | 8.18 | 8.33 | 8.41 | 8.15 | 8.3 | |
| Tangible book value per share | 7.1 | 7.43 | 7.41 | 7.07 | 7.16 | |
| Share holders equity per share | 8.18 | 8.33 | 8.41 | 8.15 | 8.3 | |
| Interest debt per share | 1.51 | 1.47 | 2.28 | 2.13 | 2.32 | |
| Market cap | 14.58B | 16.03B | 22.48B | 21.68B | 21.69B | |
| Enterprise value | 15.01B | 15.08B | 22.6B | 21.09B | 20.82B | |
| P/E ratio | 68.43 | 51.4 | 21.13 | 12.29 | 16.67 | |
| Price to sales ratio | 6.98 | 6.43 | 10.81 | 9.38 | 9.95 | |
| POCF ratio | 273.71 | 205.58 | 84.5 | 30.96 | 87.37 | |
| PFCF ratio | -183.93 | -342.8 | 587.53 | 33.89 | 151.63 | |
| P/B Ratio | 1.19 | 1.29 | 1.79 | 1.78 | 1.75 | |
| PTB ratio | 1.19 | 1.29 | 1.79 | 1.78 | 1.75 | |
| EV to sales | 7.18 | 6.05 | 10.86 | 9.12 | 9.55 | |
| Enterprise value over EBITDA | 27.99 | 56.37 | 50.47 | 44.95 | 46.55 | |
| EV to operating cash flow | 281.78 | 193.47 | 84.93 | 30.12 | 83.84 | |
| EV to free cash flow | -189.36 | -322.6 | 590.5 | 32.97 | 145.5 | |
| Earnings yield | 0 | 0 | 0.01 | 0.02 | 0.01 | |
| Free cash flow yield | -0.01 | 0 | 0 | 0.03 | 0.01 | |
| Debt to equity | 0.18 | 0.17 | 0.27 | 0.26 | 0.28 | |
| Debt to assets | 0.14 | 0.13 | 0.19 | 0.18 | 0.19 | |
| Net debt to EBITDA | 0.8 | -3.53 | 0.25 | -1.25 | -1.96 | |
| Current ratio | 4.06 | 4.38 | 3.45 | 3.46 | 3.16 | |
| Interest coverage | 44.31 | 6.03 | 12.47 | 25.9 | 20.12 | |
| Income quality | 1 | 1 | 1 | 1.59 | 0.76 | |
| Dividend Yield | 0 | 0 | 0 | 0.02 | 0 | |
| Payout ratio | 0.19 | 0.17 | 0.08 | 1.15 | 0.05 | |
| Sales general and administrative to revenue | 0.09 | -0.06 | 0.04 | -0.02 | 0.09 | |
| Research and developement to revenue | 0.06 | 0.1 | 0.08 | 0.08 | 0.09 | |
| Intangibles to total assets | 0.12 | 0.1 | 0.1 | 0.11 | 0.11 | |
| Capex to operating cash flow | -2.49 | -1.6 | -0.86 | -0.09 | -0.42 | |
| Capex to revenue | -0.06 | -0.05 | -0.11 | -0.03 | -0.05 | |
| Capex to depreciation | -1 | -0.94 | -1.76 | -0.47 | 0.42 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 2.56 | 3.13 | 5.8 | 7.36 | 6.38 | |
| ROIC | 0.02 | 0 | 0.02 | 0.03 | 0.02 | |
| Return on tangible assets | 0 | 0.01 | 0.02 | 0.03 | 0.02 | |
| Graham Net | 2.2 | 2.55 | 2.01 | 1.79 | 1.87 | |
| Working capital | 6.71B | 7.12B | 6.89B | 6.42B | 6.45B | |
| Tangible asset value | 10.61B | 11.07B | 11.07B | 10.56B | 10.7B | |
| Net current asset value | 5.1B | 5.47B | 4.75B | 4.36B | 4.49B | |
| Invested capital | 0.18 | 0.17 | 0.27 | 0.26 | 0.28 | |
| Average receivables | 3.82B | 3.6B | 3.5B | 3.42B | 3.3B | |
| Average payables | 888.03M | 885.27M | 856.13M | 815.58M | 798.82M | |
| Average inventory | 1.69B | 1.61B | 1.58B | 1.66B | 1.7B | |
| Days sales outstanding | 162.5 | 123.81 | 154.2 | 127.18 | 137.5 | |
| Days payables outstanding | 109.31 | 83.52 | 106.19 | 91.99 | 105.19 | |
| Days of inventory on hand | 206.15 | 145.72 | 207.76 | 196.04 | 224.24 | |
| Receivables turnover | 0.55 | 0.73 | 0.58 | 0.71 | 0.65 | |
| Payables turnover | 0.82 | 1.08 | 0.85 | 0.98 | 0.86 | |
| Inventory turnover | 0.44 | 0.62 | 0.43 | 0.46 | 0.4 | |
| ROE | 0 | 0.01 | 0.02 | 0.04 | 0.03 | |
| Capex per share | -0.09 | -0.08 | -0.15 | -0.04 | -0.07 |
600535.SS Frequently Asked Questions
What is Tasly Pharmaceutical Group Co., Ltd stock symbol ?
Tasly Pharmaceutical Group Co., Ltd is a CN stock and trading under the symbol 600535.SS
What is Tasly Pharmaceutical Group Co., Ltd stock quote today ?
Tasly Pharmaceutical Group Co., Ltd stock price is $15.42 today.
Is Tasly Pharmaceutical Group Co., Ltd stock public?
Yes, Tasly Pharmaceutical Group Co., Ltd is a publicly traded company.
Company Profile
- Volume Average 14.74M
- Market Capitalization 22.95B
- Employee 9.18K
- CEO Mr. Jing Su
- Headquarters Tianjin,CN
- IPO Date 2002-08-23
-
Website
https://www.tasly.com 
Tasly Pharmaceutical Group Co., Ltd. engages in biological medicine, health, and medical service businesses in China. It offers herbal and chemical medicines, health products, pharmaceutical substances and APIs, herbal extracts, concentrated herbal granules, and tea series products. The company also provides cosmetic series products, including moisture lotions, moisture creams, eye creams, and face washing foams; daily hygiene products, such as sanitary and carefree pads, honey-propolis soaps, and pollen soaps; and medical equipment, which include massage tappers, massage cushions, and circulation machines. It also exports its products to the United States, Russia, and countries in Europe, Africa, and rest of Asia. Tasly Pharmaceutical Group Co., Ltd. was founded in 1994 and is based in Tianjin, China.
